Review
CCR5 antagonists for the treatment of HIV
Affiliations
- PMID: 15600241
Item in Clipboard
Review
CCR5 antagonists for the treatment of HIV
Curr Opin Investig Drugs.
2004 Aug.
Abstract
The CCR5 chemokine receptor is expressed on a wide range of immune cell types and binding to this receptor mediates cellular entry by the majority of HIV isolates. Blocking viral entry via this receptor reduces the viral load in patients infected with HIV, suggesting that a CCR5 antagonist could become a key component in the treatment of HIV-compromised patients. A number of CCR5 antagonists are currently in clinical trials. This review details the status of leading agents and highlights recent advances in the development of new CCR5 antagonists.
Similar articles
-
The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.Curr Opin Pharmacol. 2004 Oct;4(5):447-52. doi: 10.1016/j.coph.2004.07.004. Curr Opin Pharmacol. 2004. PMID: 15351348 Review.
-
CCR5 antagonists: a new tool in fighting HIV.J HIV Ther. 2005 Dec;10(4):68-71. J HIV Ther. 2005. PMID: 16519245 Review.
-
CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on.Antivir Chem Chemother. 2010 Apr 14;20(5):179-92. doi: 10.3851/IMP1507. Antivir Chem Chemother. 2010. PMID: 20413825 Review.
-
The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.J Clin Pharm Ther. 2009 Apr;34(2):147-60. doi: 10.1111/j.1365-2710.2008.00978.x. J Clin Pharm Ther. 2009. PMID: 19250135 Review.
-
Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.Curr Opin Investig Drugs. 2009 Aug;10(8):845-59. Curr Opin Investig Drugs. 2009. PMID: 19649929 Review.
Cited by
-
Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection.J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):204-12. doi: 10.1097/QAI.0b013e3181ff2aa5. J Acquir Immune Defic Syndr. 2011. PMID: 21084994 Free PMC article.
-
Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?Neurotherapeutics. 2007 Oct;4(4):590-601. doi: 10.1016/j.nurt.2007.07.004. Neurotherapeutics. 2007. PMID: 17920540 Free PMC article. Review.
-
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32. doi: 10.1128/AAC.49.11.4721-4732.2005. Antimicrob Agents Chemother. 2005. PMID: 16251317 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical